Arrow Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Arrow Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-660	Closed	-$207K	–	338
2019 Q2	$207K	Hold	660	–	–	0.04%	168
2019 Q1	$271K	Buy	660 +600	+1,000%	+$247K	0.06%	156
2018 Q4	$22K	Hold	60	–	–	0.01%	256
2018 Q3	$24K	Hold	60	–	–	0.01%	266
2018 Q2	$21K	Hold	60	–	–	﹤0.01%	255
2018 Q1	$21K	Buy	+60	New	+$20.9K	﹤0.01%	262
2017 Q4	–	Sell	-100	Closed	-$45K	–	339
2017 Q3	$45K	Buy	+100	New	+$47.6K	0.01%	218
2014 Q2	–	Sell	-40	Closed	-$12K	–	358
2014 Q1	$12K	Buy	40 +5	+14%	+$1.54K	﹤0.01%	274
2013 Q4	$10K	Buy	35 +20	+133%	+$5.75K	﹤0.01%	266
2013 Q3	$5K	Buy	+15	New	+$3.95K	﹤0.01%	304

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Arrow Financial's REGN Position: Q3 2019 in Review

Arrow Financial sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 660 shares — an estimated $207K sold.

Arrow Financial first reported a position in REGN in Q3 2013 and held it in 10 quarters. The position peaked at $271K in Q1 2019. 633 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

Arrow Financial reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Arrow Financial sold 660 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $207K.
Arrow Financial first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Arrow Financial's Regeneron Pharmaceuticals position peaked at $271K in Q1 2019.
633 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Arrow Financial's 13F filing for Q3 2019, filed 28 Oct 2019.